BioXcel Therapeutics
Yahoo Finance • 4 days ago
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of War Clinical Practice Guidelines for manage... Full story
Yahoo Finance • last month
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today annou... Full story
Yahoo Finance • 4 months ago
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions
Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8 Topics Covered by Drs. Leslie Citrome, Marc Milano, and Leon Ravin to Include Opportunities and Advantages of Self-Administered Treatments at Home NEW HAVEN, C... Full story
Yahoo Finance • 5 months ago
BioXcel Therapeutics GAAP EPS of -$2.18 misses by $0.84
* BioXcel Therapeutics press release [https://seekingalpha.com/pr/20303392-bioxcel-therapeutics-reports-third-quarter-2025-financial-results-and-provides-update-on-late] (BTAI [https://seekingalpha.com/symbol/BTAI]): Q3 GAAP EPS of -$2.1... Full story
Yahoo Finance • 6 months ago
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in neuroscience, announced today... Full story
- PM
Mentioned:
Yahoo Finance • 7 months ago
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it ha... Full story
Yahoo Finance • 7 months ago
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p<.05) Complete resolution of agitation was significantly higher with BXCL501 compared to placeb... Full story
Yahoo Finance • 7 months ago
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT STSSW [https://www.chartmill.com/stock/quote/STSSW/profile] 86.83%... Full story
Yahoo Finance • 7 months ago
Which stocks are experiencing notable movement on Wednesday?
Intrigued by the market activity in the middle of the day on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT STSSW [https://ww... Full story
Yahoo Finance • 7 months ago
The market is filled with gapping stocks in Wednesday's session.
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT NBY [https://www.chartmill.com/sto... Full story
Yahoo Finance • 7 months ago
UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While... Full story
Yahoo Finance • 8 months ago
Get insights into the top gainers and losers of Tuesday's after-hours session.
After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE... Full story
Yahoo Finance • 8 months ago
BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025
NEW HAVEN, Conn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it wil... Full story
Yahoo Finance • 8 months ago
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Data from more than 2,600 agitation episodes collected Topline data readout is on track for August NEW HAVEN, Conn., Aug. 19, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing art... Full story
Yahoo Finance • 8 months ago
These stocks are moving in today's pre-market session
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT V... Full story
Yahoo Finance • 8 months ago
Stocks Moving Premarket: PPCB, BTAI, TNXP, DAY, TPIC, And Other Gainers & Losers
(RTTNews) - At 6.50 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell. For active traders, premarket trading offers a he... Full story
Yahoo Finance • 8 months ago
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
Achieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home (Outpatient) setting sNDA submission on track for Q1 2026 NEW HAVEN, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq... Full story
Yahoo Finance • 8 months ago
Wondering what's happening in today's after-hours session?
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT DHAI [https://www.chartmill.com/stock/quote/DHAI/profile... Full story
Yahoo Finance • 8 months ago
BioXcel Therapeutics receives FDA feedback ahead of planned pre-sNDA meeting
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced Thursday that it has received preliminary comments from the U.S. Food and Drug Administration (FDA) in advance of a pre-supplemental New Drug Application (pre-sNDA) meeting scheduled for A... Full story
